Understanding clinical therapies on cognitive function is an important aspect of the drug discovery process. Objective cognitive testing (not based on self-reported measures) in early phase clinical trials could provide insight to subtle but important effects on a subject’s ability to perceive, process, understand and store information, make decisions and produce appropriate responses.
This understanding can benefit the drug discovery process by informing decisions to progress candidate compounds, dose-response relationships, selection of safe doses, detection of off-target effects and risk: benefit to the target indication.
Cognitive testing can be deployed at pre-screening to ensure you have appropriate participants on your study and in-study to assess compound effects on different cognitive domains such as:
- Memory and recall
- Processing/reaction speed
- Speech and language
- Attention/Executive functions
Contact us to discuss any cognitive testing you need for your clinical trial.
The Science Behind can help Sponsors and CROs with some of these challenges in Phase 1 trials by providing the tools and specialist expertise to answer key questions in relation to safety and efficacy when bringing novel drug candidates to human clinical trials.